Chromatin Signaling and Diseases

2nd Edition - September 1, 2024
Editors: Olivier Binda, Martin Ernesto Fernandez-Zapico, Ana Sevilla Hernandez
Language: English
Paperback ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 0 0 1 - 8
Hardback ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 0 0 1 - 8
eBook ISBN:
9 7 8 - 0 - 4 4 3 - 1 9 0 0 2 - 5

Chromatin Signaling and Diseases, Second Edition, a volume in the Translational Epigenetics series, covers the molecular mechanisms that regulate gene expression, which govern… Read more

Purchase options

Limited Offer

Save 50% on book bundles

Immediately download your ebook while waiting for your print delivery. No promo code needed.

Institutional subscription on ScienceDirect

Request a sales quote

Chromatin Signaling and Diseases, Second Edition, a volume in the Translational Epigenetics series, covers the molecular mechanisms that regulate gene expression, which governs embryonic development, growth, and human pathologies associated with aging, such as cancer. Although human genome sequencing continues to improve, molecular mechanisms regulating gene expression remain largely misunderstood. The impact of gene expression defects associated with malfunctioning chromatin signaling are considered in this update. In addition, this new edition has addresses developments in the field, from phase separation of membrane-less organelles and local segregation of factors to chromatinization of naked foreign DNA and cancer evolution as regulated by chromatin signaling.

Chromatin signaling proposes that small protein domains recognize chemical modifications on the genome scaffolding histone proteins, facilitating the nucleation of enzymatic complexes at specific loci that then open up or shut down the access to genetic information, thereby regulating gene expression. The addition and removal of chemical modifications on histones, as well as the proteins that specifically recognize these are also considered.

Olivier Binda

Dr. Olivier Binda is a Researcher at the University of Ottawa, specializing in epigenetics and gene expression as it relates to human diseases. Dr. Binda co-edited Chromatin Signaling and Diseases (Elsevier 2016), a volume in Elsevier’s Translational Epigenetics series, and has published 20 scientific papers in such peer reviewed journals as the Molecular Cell, Journal of Biological Chemistry, Biochemistry, Epigenetics, Oncogene, Scientific Reports, and Stem Cell Research. In past positions he has served as a postdoctoral fellow at McGill University and Stanford University, and he completed his PhD in Biochemistry at McGill University in 2007.

Affiliations and expertise

University of Ottawa, Department of Cellular and Molecular Medicine, Ottawa, CANADA.

Affiliations and expertise

Principal Investigator, Newcastle Cancer Centre, Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK

Martin Ernesto Fernandez-Zapico

The research program of Martin E. Fernandez-Zapico, M.D., focuses on the cellular and molecular characterization of epigenetic pathways regulating pancreatic carcinogenesis, a dismal disease with one of the poorest prognoses among all neoplasms. Specifically, Dr. Fernandez-Zapico and his team study the modulation of chromatin and nuclear dynamics by oncogenic cascades and its impact in gene expression regulation, a critical step during pancreatic neoplastic transformation.

Dr. Fernandez-Zapico and his team are confident that the knowledge derived from his studies will help with the understanding of the contribution of these epigenetic events to the initiation and/or progression of pancreatic carcinogenesis as well as serve as a foundation for the development of new therapeutic approaches.

Dr. Fernandez-Zapico's program is affiliated with the Mayo Clinic Cancer Center, Department of Oncology, Division of Gastroenterology and Hepatology, and the Center for Cell Signaling in Gastroenterology. His research is supported by the National Institutes of Health (NIH), the NIH-funded Mayo Clinic Pancreatic Cancer Specialized Program of Research Excellence (SPORE), the NIH-funded Mayo Clinic Center for Cell Signaling in Gastroenterology, and the Leukemia and Lymphoma Foundation.

Affiliations and expertise

Associate Professor of Medicine, Associate Professor Pharmacology, Mayo Institute, Rochester, MN, USA

Ana Sevilla Hernandez

Ana Sevilla Hernandez is Head of the Stem Cells in the Development and Disease Lab, Department of Cell Biology, Physiology and Immunology, Faculty of Biology, Barcelona University, Spain.

Affiliations and expertise

Head of the Stem Cells, Development and Disease Lab, Department of Cell Biology, Physiology and Immunology, Faculty of Biology, Barcelona University, Spain